explore -WSS

explore

author：comprehensive 2025-10-01 22:16:34 - browse：83259

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： UpToDate has a racism problem: Dr. Stanley Goldfarb

WSS

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Virtual repurposing can help discover new uses for existing drugs

The biotech scorecard for Q3: 15 stock

Drug cartel violence flares in western Mexico after vigilante leader's killing

knowledge

explore

hotspot

In Memoriam: Notable people who died in 2023

Hubble vs. James Webb telescope images: See the difference

Continuity nursing helped my family in our darkest PICU moments

Color Health wants to make cancer screenings convenient

Drug repurposing or repositioning? The language matters

How Robert F. Kennedy Jr. distorted vaccine science

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Skip the lead apron during X

ChatGPT in medicine: STAT answers readers' burning questions

Canadians with cystic fibrosis outlive Americans by a decade

Wikipedia

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

A letter from the executive editor: The 2023 STATUS List

'Screen and refer' systems are hurting patients

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Canadians with cystic fibrosis outlive Americans by a decade

Lupron, used to halt puberty in children, may cause lasting health problems

entertainment

hotspot

focus

entertainment